Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia

References

• Peralta G, Sanchez MB, Garrido JC, De Benito I, Cano ME, Martinez-Martinez L, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60:855–63.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50:40–8.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010;54: 4085–91.
   PubMed Web of Science ®Google Scholar
• Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851–63.
   PubMed Web of Science ®Google Scholar
• Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009;64(Suppl 1): i3–10.
   PubMedGoogle Scholar
• Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012;9:283–94.
   Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta- lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657–86.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta- lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159–66.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Cisneros JM, Pena C, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2010;48:1726–31.
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682–90.
   PubMed Web of Science ®Google Scholar
• Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M, Delgado A, Horcajada JP, et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis 2012;12:245.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008;52:3244–52.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987–94.
   PubMed Web of Science ®Google Scholar
• Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012;67:1311–20.
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011; 86:250–9.
   PubMed Web of Science ®Google Scholar
• Nasa P, Juneja D, Singh O, Dang R, Singh A. An observational study on bloodstream extended-spectrum beta- lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur J Intern Med;23:192–5.
   Google Scholar
• Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010;54:3590–6.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Lopez-Prieto MD, Portillo MM, Retamar P, Natera C, Nuno E, et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect 2010;16:1408–13.
   PubMed Web of Science ®Google Scholar
• de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66:398–407.
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913–20.
   PubMed Web of Science ®Google Scholar
• Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta- lactamases. Antimicrob Agents Chemother 2010;54:5099–104.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–96.
   PubMed Web of Science ®Google Scholar
• Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010;54:1742–8.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sanchez-Ortega I, et al. Bacteraemia due to multidrug- resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011;66:657–63.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011;55: 3485–90.
   PubMed Web of Science ®Google Scholar
• Llewelyn MJ, Cohen J. Tracking the microbes in sepsis: advancements in treatment bring challenges for microbial epidemiology. Clin Infect Dis 2007;44:1343–8.
   PubMed Web of Science ®Google Scholar
• http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/table_reports.aspx
   Google Scholar
• Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250–6.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–83.
   PubMedGoogle Scholar
• Hall BG, Barlow M. Evolution of the serine beta-lactamases: past, present and future. Drug Resist Updat 2004;7: 111–23.
   PubMed Web of Science ®Google Scholar
• Referensmetodik för laboratoriediagnostik vid kliniskt mikrobiologiska laboratorier [database on the Internet] [cited 12 July 2012]. Available at: http://www.referensmetodik.smi.se/w/Referensmetodik:_Tarminfektioner
   Google Scholar
• http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/EUCAST_guidelines_detection_of_resistance_mechanisms_121222
   Google Scholar
• Hsieh CJ, Shen YH, Hwang KP. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum beta-lactamase (ESBL) and non-ESBL producing Escherichia coli. J Microbiol Immunol Infect 2010;43:240–8.
   PubMedGoogle Scholar
• Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010;54:3564–8.
   PubMed Web of Science ®Google Scholar
• Tham J, Odenholt I, Walder M, Andersson L, Melander E. Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli in a county of Southern Sweden. Infect Drug Resist 2013;6:93–7.
   PubMedGoogle Scholar
• Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended- spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70:150–3.
   Google Scholar
• Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram- negative bacilli. Antimicrob Agents Chemother 2008;52: 813–21.
   PubMed Web of Science ®Google Scholar
• Harbarth S, Nobr V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44:87–93.
   PubMedGoogle Scholar
• Marschall J, Agniel D, Fraser VJ, Doherty J, Warren DK. Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes. J Antimicrob Chemother 2008;61:1376–83.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008;61:436–41.
   PubMed Web of Science ®Google Scholar